Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Personalized Neoantigen Cancer Vaccines

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03794128
Recruitment Status : Completed
First Posted : January 4, 2019
Last Update Posted : September 11, 2020
Sponsor:
Information provided by (Responsible Party):
Gritstone Oncology, Inc.

Brief Summary:
The purpose of this study is 1) to evaluate the feasibility of manufacturing a patient-specific neoantigen cancer vaccine, which involves predicting the patient's neoantigens and generating a vaccine that encodes the predicted neoantigens; and, 2) to identify and select patients who may be eligible for a shared neoantigen cancer vaccine where their tumor contains a specific shared mutation and who have the correct HLA allele capable of presenting the neoantigen derived from the tumor-specific mutation.

Condition or disease Intervention/treatment
Non Small Cell Lung Cancer Colorectal Cancer Gastroesophageal Adenocarcinoma Urothelial Carcinoma Pancreatic Ductal Adenocarcinoma Procedure: Blood collection for research (next-generation sequencing [NGS]) Procedure: Blood collection for research (HLA typing)

Detailed Description:

Gritstone is developing two neoantigen-based cancer vaccines: the first is a patient-specific cancer vaccine that requires a manufacturing period for each patient and the second is an off-the-shelf cancer vaccine that targets shared neoantigens.

The process of generating a patient-specific neoantigen cancer vaccine involves multiple steps, including collection of patient tumor and blood specimens, performing next-generation sequencing (NGS), predicting the neoantigens to be included in the patient-specific vaccine, and the manufacture and release of the patient-specific vaccine. Gaining experience in managing the manufacturing process will provide important insights and experience regarding this process to be used in operationalizing future clinical trials.

Selecting patients who may be eligible to receive a shared neoantigen vaccine requires first identifying patients whose tumor possesses a neoantigen derived from an oncogenic mutation that is encoded by the vaccine, and then determining whether the patient expresses a matching HLA allele for antigen presentation.

Study participants will not receive any investigational treatment as part of this trial. Patients screened in this study may be able to enroll in a separate investigational treatment study sponsored by Gritstone Oncology, provided that the patient meets the specified eligibility criteria for that treatment study.

Layout table for study information
Study Type : Observational
Actual Enrollment : 93 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: An Observational Feasibility Study for the Production of a Patient-Specific Neoantigen Cancer Vaccine and Screening Study for a Shared Neoantigen Cancer Vaccine in Patients With Advanced Cancer
Actual Study Start Date : July 25, 2018
Actual Primary Completion Date : January 17, 2020
Actual Study Completion Date : May 26, 2020

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
1 - patient-specific neoantigen cancer vaccine production Procedure: Blood collection for research (next-generation sequencing [NGS])
Participants will have whole blood collected for next-generation sequencing (NGS).

Procedure: Blood collection for research (HLA typing)
Participants will have whole blood collected for HLA typing.

2 - shared neoantigen cancer vaccine screening Procedure: Blood collection for research (HLA typing)
Participants will have whole blood collected for HLA typing.




Primary Outcome Measures :
  1. Group 1 only: Presence of neoantigens sufficient to warrant patient-specific vaccine manufacture [ Time Frame: At study enrollment ]
  2. Group 1 only: Percentage of patients for whom patient-specific vaccine is successfully manufactured (defined as meeting release criteria) [ Time Frame: Up to approximately 20 weeks ]
  3. Group 2 only: Percentage of patients with at least one of the twenty specified shared mutations contained in the expression cassette and a matching HLA allele for neoantigen presentation [ Time Frame: Up to approximately 2 weeks ]

Biospecimen Retention:   Samples With DNA
  • whole blood specimen, for HLA typing (all participants)
  • FFPE tumor material from a biopsy or resection, for sequencing to identify tumor-specific mutations (Group 1 participants only)
  • whole blood specimen, for sequencing of normal genome (Group 1 participants only)


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Oncology
Criteria

Group 1 Inclusion Criteria:

  • Provide a signed and dated informed consent form prior to initiation of study-specific procedures
  • Patients with the indicated advanced or metastatic solid tumor as follows:

    1. NSCLC who have received ≤ 1 cycle of systemic treatment with cytotoxic, platinum-based chemotherapy (Note: patients with NSCLC who are receiving pembrolizumab monotherapy as first line systemic monotherapy are eligible)
    2. GEA who have received ≤ 1 cycle of systemic treatment with cytotoxic, platinum-based chemotherapy
    3. mUC who have received ≤ 1 cycle of systemic treatment with cytotoxic, platinum-based chemotherapy
    4. CRC-microsatellite stable (MSS) who have received ≤ 1 cycle of second line systemic therapy including a fluoropyrimidine and oxaliplatin or irinotecan (Note: patients receiving first-line systemic therapy are eligible)
  • 18 years of age or older
  • ECOG Performance Status 0 or 1
  • Available FFPE tumor specimen for sequencing and neoantigen selection
  • Measurable disease according to RECIST v1.1 Have adequate organ function, as measured by laboratory values (criteria listed in protocol)

Group 1 Exclusion Criteria:

  • Tumors with genetic characteristics as follows:

    1. For NSCLC, patients with a known driver genomic alteration in EGFR, ALK, ROS1, RET, or TRK
    2. For CRC or GEA, patients with MSI disease
    3. For CRC, patients with a known BRAF mutation or patients with peritoneal carcinomatosis

Group 2 Inclusion Criteria:

  • Provide a signed and dated informed consent form prior to initiation of study-specific procedures
  • Patient's tumor possesses one of the mutations listed in the clinical study protocol, as determined per local institutional standard
  • Patients with an advanced or metastatic solid tumor as follows:

    1. MSS-CRC who are currently receiving systemic treatment with a fluoropyrimidine and oxaliplatin or irinotecan that may include a VEGF or EGFR targeting therapy as their first-line or second-line therapy for metastatic disease
    2. NSCLC who are currently receiving systemic treatment with cytotoxic, platinum-based chemotherapy in combination with an anti-PD-(L)1 antibody
    3. PDA who are currently receiving systemic cytotoxic chemotherapy as their first-line therapy for metastatic disease

Group 2 Exclusion Criteria

  • Patients with MSI disease
  • Patients with NSCLC with a known driver genomic alteration in EGFR, ALK, ROS1, RET, or TRK

Complete inclusion and exclusion criteria are listed in the clinical study protocol.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03794128


Locations
Layout table for location information
United States, Illinois
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States, 60637
United States, New York
Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center
New York, New York, United States, 10032
United States, Ohio
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210
United States, Tennessee
Tennessee Oncology
Nashville, Tennessee, United States, 37203
United States, Virginia
Virginia Cancer Specialists
Fairfax, Virginia, United States, 22031
Sponsors and Collaborators
Gritstone Oncology, Inc.
Layout table for additonal information
Responsible Party: Gritstone Oncology, Inc.
ClinicalTrials.gov Identifier: NCT03794128    
Other Study ID Numbers: GO-003
First Posted: January 4, 2019    Key Record Dates
Last Update Posted: September 11, 2020
Last Verified: September 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gritstone Oncology, Inc.:
neoantigen cancer vaccine
personalized neoantigen cancer vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Carcinoma, Transitional Cell
Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type